Experience

Davis Polk advised the sole structuring advisor and sole bookrunner in a Rule 144A offering by Impax Laboratories, Inc. of its 2.00% convertible senior notes due 2022. In addition,…

Davis Polk advised the underwriters in connection with the $72.5 million U.S. initial public offering of 5,175,000 common shares of Cynapsus Therapeutics Inc., including 675,000 common…

Davis Polk advised Biotie Therapies Corp. (“Biotie”) on its $56.7 million U.S. initial public offering of 3,806,047 American Depositary Shares (“ADSs”) representing 304,483,760 ordinary…

Davis Polk advised the underwriters as joint global coordinators on the initial public offering and listing on the Main Board of the Stock Exchange of Hong Kong Limited of 3SBio Inc. …

Davis Polk advised Auris Medical Holding AG (“Auris Medical”) on its $25.1 million public offering of 5,275,000 of its common shares. The common shares are listed on the NASDAQ Global…

Davis Polk advised the several underwriters, in connection with Galapagos NV’s global offering of 7,532,499 of its ordinary shares. The offering consisted of an underwritten public…

Davis Polk advised the joint book-running managers in connection with a registered public offering by Anthem, Inc. of $1.25 billion aggregate stated amount of its equity units, including …

Davis Polk advised the joint book-running managers and representatives of the underwriters on a public offering by Laboratory Corporation of America Holdings (LabCorp) of $500 million…

Davis Polk is advising Warner Chilcott plc in connection with its approximately $8.5 billion acquisition by Actavis, Inc. in a stock-for-stock transaction. The transaction is expected to…